Sumitomo Dainippon Pharma and SanBio Conclude Joint Development and License Agreement for North AmericaJoint Development and License Agreement • September 23rd, 2014
Contract Type FiledSeptember 23rd, 2014Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada) (“Sumitomo Dainippon Pharma”) and SanBio Co., Ltd. (Head Office: Chuo-ku, Tokyo, Japan; President: Keita Mori), acting through its U.S. subsidiary SanBio, Inc. (Head Office: Mountain View, California, USA) (“SanBio”), announced today that the two companies have entered into a joint development and license agreement for exclusive marketing rights in the